Product science guide · Sources checked October 5, 2026
GLP-1 and GIP are hormone signals discussed in diabetes and weight-management research. The main distinction between semaglutide and tirzepatide is their receptor activity: semaglutide acts at the GLP-1 receptor, while tirzepatide acts at both GIP and GLP-1 receptors. Understanding those terms helps you read a study or medicine description without mistaking a mechanism for a personal treatment recommendation.
This guide explains the vocabulary and the questions it can answer. It does not provide dosing, switching instructions or a ranking of treatments for an individual.
GLP-1 vs GIP at a glance
| Term | What it means here |
|---|---|
| GLP-1 | Glucagon-like peptide-1, a hormone involved in blood-glucose and appetite regulation. |
| GIP | Glucose-dependent insulinotropic polypeptide, another hormone signal involved in glucose regulation. |
| Receptor agonist | A substance that activates a receptor. In these medicine descriptions, the receptor name identifies the signaling system being acted on. |
| Semaglutide | A GLP-1 receptor agonist. |
| Tirzepatide | A dual GIP and GLP-1 receptor agonist. |
NIDDK identifies these medication classes in its overview of weight-management medicines in diabetes care. Its patient guide describes how the hormone pathways relate to appetite and food intake.
How semaglutide and tirzepatide descriptions differ
A semaglutide description usually emphasizes GLP-1 activity. A tirzepatide description may use “dual agonist,” “GIP/GLP-1” or “dual incretin.” In this context, “dual” describes tirzepatide's activity at two receptor types. It does not mean that a reader should combine two medicines.
Keep three details separate when reading a product page: the active ingredient, the exact medicine or formulation, and the condition being discussed. An ingredient name alone does not supply the full prescribing information. NIDDK's patient guide distinguishes medicines marketed under different names and directs readers to the FDA drug database for product information.
What the mechanism cannot tell you
Receptor activity is one part of a medicine's description. It does not, by itself, tell you the size of a clinical benefit, how often adverse effects occur, or whether a treatment fits your medical history. Those questions require clinical evidence and an assessment by a qualified health professional.
When a comparison cites results, record the participants, treatment duration, outcome and comparison group. A percentage from one study is hard to interpret if another study followed a different population for a different length of time. This is a reading method, not a claim that every comparison is invalid.
Questions to bring to a clinical discussion
- Which exact medicine and formulation are we discussing?
- What treatment goal does it address in my situation?
- Which evidence supports that goal, and how closely do the study participants match my circumstances?
- Which risks, interactions and follow-up checks matter for me?
NIDDK recommends reviewing medical history, prescribing information, tolerability and other medicines when considering treatment. Use our GLP-1 follow-up appointment checklist to organize your questions, and our side-effects guide for additional background.
Common terminology questions
Is tirzepatide a GLP-1 medicine?
It acts at GLP-1 receptors and GIP receptors. “Dual GIP and GLP-1 receptor agonist” is the more precise class description.
Does dual action automatically mean the right choice for me?
No. A mechanism label cannot replace a discussion of the exact medicine, evidence, risks and your treatment goals.
Can this guide tell me how to switch medicines?
No. It explains terms. Starting, stopping or switching a prescription requires guidance from your treating clinician.
Written as general education by the MyGLP1Reviews editorial team. No medical-review credential or individual treatment assessment is claimed. See how we review and our medical disclaimer.